Indeed, it has been reported that Tregs can inhibit the expression of costimulatory ligands on DCs, thereby restraining CD8+ T cell activation and tumor clearance in a Kras-mutant model for pancreatic cancer (Jang et al. 2017). Here, CD8A is linked to neoplasm.